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A great majority of cardiac rhythm devices (pace-
makers, implantable cardioverter defibrillators, 
and cardiac resynchronization therapy) are 
placed percutaneously through the central veins, 
across the tricuspid valve, and inserted into the 
endocardium. Recent data have emphasized that 
central venous stenosis and infection associated 
with transvenous leads can be observed in hemo-
dialysis patients dialyzing with an arteriovenous 
access or a tunneled hemodialysis catheter.1 
The development of stenosis not only produces 
symptoms but can also have a direct impact, 
decreasing dialysis dose by restricting blood 
flow. Because the leads of a transvenous cardiac 
rhythm device are directly exposed to blood, they 
are vulnerable to contamination during episodes 
of bacteremia, often necessitating the removal of 
a life-supporting device.1 Finally, transvenous 
leads can injure the valve and produce severe 
tricuspid regurgitation.2
In contrast to transvenous cardiac devices, epi-
cardial leads traverse the subcutaneous tissue and 
are implanted into the epicardium (Figure 1).1 
In doing so, these leads completely bypass the 
central veins and the tricuspid valve and do not 
serve as a culprit for central venous stenosis, 
lie in the pathway of blood, or cause tricuspid 
regurgitation. This report focuses on transvenous 
lead-associated central venous stenosis, infection, 
and tricuspid regurgitation and highlights epi-
cardial leads as an alternative (Table 1). Because 
the effectiveness of the epicardial leads is often 
brought into question, this report also provides 
information regarding the functionality of the 
epicardial versus a transvenous system.3
Central venous stenosis is a recurrent prob-
lem that is frequently observed with the use of 
transvenous leads.4 The complication has been 
observed in up to 70% of non-hemodialysis-
dependent patients, but patients are seldom 
symptomatic. The situation is vastly differ-
ent in end-stage renal disease patients with 
transvenous cardiac devices who are receiving 
dialysis therapy with an arteriovenous access in 
the upper extremity. Here, a great majority of 
patients (>70%) become symptomatic, perhaps 
because of high flow of an arteriovenous access 
in comparison with patients with no access in 
the upper extremity.
Ligation of the dialysis access controls the 
symptoms. However, the lifeline of a dialysis 
patient is lost. It is generally believed that the 
symptoms of central stenosis are less common 
when the arteriovenous access is located contra-
lateral to the cardiac device. Although ligation 
and placement of a new arteriovenous access 
in the opposite arm have been the highlighted 
options, they are associated with multiple major 
limitations. First, this approach leads to the loss 
of the existing lifeline. Second, the methodology 
results in a total loss of the entire venous capital 
in the upper extremity ipsilateral to the cardiac 
device. Third, the superior vena cava is the final 
pathway for the leads. Because the leads traverse 
this structure, stenosis can also develop in this 
vein.1,4 While many have documented the devel-
opment of lead-induced superior vena cava ste-
nosis, a recent multicenter study confirmed the 
presence of this lesion and recorded an incidence 
of nearly 18%.4 In such a scenario, the presence 
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Table 1 | Advantages of epicardial approach for renal patients
Epicardial cardiac devices Transvenous cardiac devices Reference number
Central venous stenosis Not observed Common 1,4
Infection Uncommon Not uncommon 1
Preservation of central  
venous real estate
Available Compromised
Tricuspid valve problems Absent Present 2
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of stenosis will cause symptoms regardless of 
the side of the cardiac device and arteriovenous 
access. Fourth, stenotic lesions can occur at 
multiple sites and can subsequently include an 
area that was previously normal. In one study, 
patients who initially presented with lead-
induced brachiocephalic lesions subsequently 
developed superior vena cava stenosis.1 Place-
ment of a new access contralateral to the cardiac 
device and ligation of the ipsilateral access in 
this scenario would have resulted in the loss of 
venous capital ipsilateral to the cardiac device 
without any impact on clinical features of central 
venous stenosis. Epicardial leads bypass the cen-
tral veins altogether and provide a meaningful 
solution to a difficult problem.1
Balloon angioplasty has also been used for the 
treatment of central venous stenosis; however, 
the problem recurs frequently, and the results are 
short lived (primary patency rates = 18% and 9% 
at 6 and 12 months, respectively).4 Endovascular 
stents have also not established a conclusive role 
in the management of lead-associated stenosis. 
Because of the risk of lead entrapment, a stent 
can complicate future lead removal. If the infec-
tion involved the lead, the removal would require 
a major thoracotomy procedure. It is for this rea-
son that the recent Heart Rhythm Society expert 
consensus on transvenous lead extraction rec-
ommendations do not support stent placement 
over the leads (class I indication).5 The epicardial 
approach would completely bypass these issues.
Repeated cannulation (skin break) of an 
arterio venous access and opening of catheter 
ports with each dialysis create a possible portal 
for bacterial entry to the bloodstream. The intra-
vascular location of the leads and close proximity 
to the catheter potentially make the leads vul-
nerable to bacterial seeding with each dialysis 
session.1 In a retrospective analysis, seven of 
nine consecutive chronic hemodialysis patients 
with transvenous cardiac devices presented with 
access infection.1 Four of the seven patients were 
receiving hemodialysis via a catheter and three 
with an arterio venous graft. The four patients 
with catheters were seen for catheter-related bac-
teremia. The infection (Staphylococcus aureus) 
spread to the transvenous cardiac devices. All 
four catheter patients demonstrated lead-associ-
ated vegetation on transesophageal echocardio-
gram and required cardiac device removal along 
with the catheter.1 The three patients with arte-
riovenous grafts experienced graft-related bac-
teremia that spread to the transvenous cardiac 
device (S. aureus). All three required graft and 
cardiac device removal to control infection.
All seven patients received epicardial car-
diac devices after the resolution of bacteremia. 
One patient switched to peritoneal dialysis, and 
six received a new hemodialysis catheter. The 
peritoneal dialysis patient had two episodes 
of peritonitis with no evidence of epicardial 
device infection over a follow-up of 2 years. The 
six hemodialysis catheter patients have suffered 
1.5 episodes of catheter-related bacteremia per 
patient at an average follow-up of 14.5 months.1 
Importantly, none of these six patients experi-
enced epicardial system infection.
Transvenous endocardial leads of a cardiac 
device can cause tricuspid regurgitation. Recently, 
a large retrospective study evaluated the role of 
transvenous cardiac rhythm device leads in the 
development of severe tricuspid regurgitation.2 
The investigators examined 156 transvenous 
cardiac device patients with severe symptomatic 
regurgitation (New York Heart Association 
functional class III or IV). All underwent sur-
gical repair. At the time of surgery, 41 patients 
(26.2%) were found to have direct evidence of 
valve damage due to the leads’ leading to severe 
symptomatic regurgitation. Operative findings 
included lead adherence to the valve (n = 14), 
lead-induced perforation of the valve (n = 7), 
lead-induced impingement of the valve (n = 16), 
and lead entanglement (n = 4). The strength of 
the study was the fact that direct surgical evi-
dence of valvular involvement was documented, 
compared with indirect measures.
Multiple mechanisms help explain the devel-
opment of lead-induced tricuspid regurg itation.2 
Transvenous endocardial leads can cause fibro-
sis and thereby induce adhesion to the valve. 
This makes the valve stiff and interferes with its 
Figure 1 | Endocardial and epicardial cardiac rhythm devices. (a) Three-dimensional 
color computed tomography scan. Tesio catheters and the leads are seen traversing the 
superior vena cava (SVC). Fibrous tissue wrapping these structures is also seen in the SVC. 
(b) Notice that the leads of an epicardial pacemaker are traversing the subcutaneous tissue 
(double arrow) to reach the epicardium (arrows), completely bypassing the central veins 
(seen on angiogram) and the tricuspid valve.
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function.2,4 Impingement, entanglement of the 
valve, and perforation can also be caused by trans-
venous leads and result in regurgitation.2 Tricuspid 
regurgitation is associated with decreased patient 
survival, and bypassing this problem with epicar-
dial leads would be a major plus.
It is important to mention that pacing in chil-
dren frequently occurs through the epicardial 
leads. This is largely due to cardiac anatomy, lim-
ited venous access, and small size of the children 
and, to some extent, is done to preserve the central 
venous system. Concerns have been raised regard-
ing the effectiveness and survival of epicardial 
leads compared with endocardial leads. Recently, 
however, Cohen et al.3 reported their 17-year 
experience (over 1200 outpatient visits) of over 
200 epicardial leads. The 1-, 2-, and 5-year lead 
survival was 96%, 90%, and 74%, respectively, in 
this long-term study. The authors concluded that 
epicardial leads provided stable acute and chronic 
sensing and pacing thresholds and demonstrated 
lead survival that was similar to that of endocardial 
leads.3 It is worth mentioning that multiple other 
studies evaluating epicardial versus endocardial 
leads found no meaningful differences in func-
tion, survival, lead recalls, or fracture. Because of 
these similarities, epicardial leads are particularly 
relevant in renal failure patients receiving hemo-
dialysis therapy.
Recently, an entirely subcutaneous implantable 
cardioverter defibrillator has been highlighted 
that is capable of successfully terminating ven-
tricular fibrillation and tachycardia. Although 
preliminary results are encouraging, there is a 
great need to determine the optimal configura-
tion of these devices.
Preservation of central venous real estate is 
critically important. Even in patients with peri-
toneal dialysis, avoiding venous endothelial irri-
tation induced by transvenous leads would be 
beneficial. With epicardial leads, central veins 
are preserved and available for vascular access.
In summary, epicardial cardiac rhythm devices 
offer important advantages for renal patients. In 
this context, they provide a promising alterna-
tive to a transvenous approach. A randomized 
controlled trial comparing the two approaches 
in renal patients is in order.
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